More urgent claims exist on limited research funding

The argument

Opponents argue that the case for this research is usually made as though funding were unconstrained. It is not: money directed to slowing ageing is money not directed elsewhere, and opponents argue that the alternatives have stronger claims. Illnesses that kill children, deaths in childbirth, infectious disease, untreated mental illness and injuries from unsafe work and traffic affect people now, often have known and inexpensive remedies, and are concentrated among those with least. Against these, opponents argue, a programme aimed at a biological process not yet shown to be modifiable in humans is a poor use of a limited budget. The risk profile is said to compound the point. Ageing research must be tested over long periods, in populations followed for decades, before anyone can say whether an intervention works, and the field has produced repeated findings in animals that did not carry across. Opponents argue that committing substantial funding to a question that may not be answerable within a working lifetime diverts both money and the scarce researchers who could be working on problems where the path from study to benefit is already understood. There is also the possibility that success would make things worse. Opponents point out that the promise of more healthy years depends on decline being postponed evenly, and that an intervention which extended life while slowing only some aspects of ageing would add years of dependence instead. Since the longest-lived people already tend to accumulate the chronic conditions that medicine manages rather than cures, opponents argue the realistic result of partial success is a larger population living with more illness for longer, which is the outcome that already strains health and care systems and the one the research was supposed to relieve.

Premises

Counter-arguments

Supporters argue that the comparison is misleading, because the conditions said to be more urgent are mostly limited by delivery, politics and infrastructure rather than by missing science, so money moved out of ageing research would not buy the remedies named. They add that the diseases of later life already consume the largest share of health spending, which makes the underlying process a reasonable target rather than a luxury. On the risk of more frail years, they argue the objection assumes the research would fail in a particular way, when the explicit aim is to extend healthy life and the same uncertainty attaches to any novel field, including ones that later transformed medicine.

Rejecting the premises

[Rejecting P1] The conditions named are limited mainly by delivery, politics and infrastructure rather than by missing science, so funds moved out of ageing research would not buy the remedies listed. [Rejecting P2] Long timescales and animal results that did not translate describe the difficulty of the field rather than its value, and the same was said of fields that later transformed medicine. [Rejecting P3] The possibility of partial success adding dependent years assumes a specific failure mode, when the stated aim and the measures used are years of health rather than years of life. [Rejecting C] Diseases of later life already consume the largest share of health spending, which makes the shared process a reasonable target rather than a luxury competing with urgent needs.